Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT00703326 Completed - Breast Cancer Clinical Trials

Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer

Start date: August 6, 2008
Phase: Phase 3
Study type: Interventional

The objective of this study is to compare the progression-free survival (PFS) of the drug combination ramucirumab plus docetaxel to placebo plus docetaxel in previously untreated participants with human epidermal growth factor receptor 2 (HER2)-negative, unresectable, locally-recurrent or metastatic breast cancer.

NCT ID: NCT00702858 Completed - Breast Cancer Clinical Trials

Trial of Blue Citrus Compared to Placebo in Patients Receiving Aromatase Inhibitor Therapy for Estrogen Receptor Positive Post-Menopausal Breast Cancer

Start date: April 2008
Phase: N/A
Study type: Interventional

This purpose of this study is to determine if the herbal compound, Blue Citrus, decreases joint and bone pain associated with Aromotase Inhibitor therapy (AIT). Another purpose of the study is to find out if Blue Citrus improves how you feel while taking AIT and if your quality of life improves.

NCT ID: NCT00699491 Completed - Clinical trials for Recurrent Breast Carcinoma

Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Start date: October 31, 2008
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial is studying the side effects and best dose of cixutumumab when given together with temsirolimus and to see how well they work in treating patients with breast cancer that has recurred (come back) at or near the same place as the original (primary) tumor or has spread to other places in the body. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways by targeting certain cells. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving cixutumumab together with temsirolimus may be a better treatment for breast cancer.

NCT ID: NCT00696527 Completed - Clinical trials for Infiltrative Breast Cancer

National Survey on Infiltrative Breast Cancer

CSI
Start date: June 2007
Phase: N/A
Study type: Observational

The purpose of this observational study is to describe radiological, clinical and histological characteristics of women with infiltrative breast cancer.

NCT ID: NCT00696072 Completed - Clinical trials for Metastatic Breast Cancer

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

Start date: August 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out what effect the combination of letrozole (brand name: Femara) and dasatinib (brand name: Sprycel) has on metastatic breast cancer compared to letrozole alone

NCT ID: NCT00694577 Completed - Clinical trials for Ductal Breast Cancer

Partial Breast Irradiation (PBI) for Selected Patients With Early Invasive or Non-Invasive Breast Cancer

Start date: September 2003
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the feasibility of partial breast irradiation in participants with early invasive or non-invasive breast cancer.

NCT ID: NCT00694252 Completed - Clinical trials for Metastatic Breast Cancer

Lapatinib and Circulating Tumor Cells in Breast Cancer

Start date: July 2008
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy of lapatinib in eradicating chemo- resistant tumour cells circulating in the blood of patients with breast cancer.

NCT ID: NCT00693719 Completed - Breast Cancer Clinical Trials

Irinotecan and Etoposide in Treating Patients With Recurrent, Locally Advanced, or Metastatic Breast Cancer

Start date: August 2007
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as irinotecan and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving irinotecan together with etoposide works in treating patients with recurrent, locally advanced, or metastatic breast cancer.

NCT ID: NCT00692289 Completed - Breast Cancer Clinical Trials

Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer

RADAR II E
Start date: June 2008
Phase: N/A
Study type: Observational

This is an open label, non-interventional quality of life analysis for Arimidex treated postmenopausal patients in early breast cancer by investigator's questionnaire

NCT ID: NCT00691678 Completed - Breast Cancer Clinical Trials

Glucosamine and Chondroitin for Aromatase Inhibitor Induced Joint Symptoms in Women With Breast Cancer

Start date: October 2008
Phase: Phase 2
Study type: Interventional

Investigators are hoping to learn if glucosamine with chondroitin can help relieve joint pain/stiffness associated with aromatase inhibitors.